{"id":505659,"date":"2021-06-22T16:19:30","date_gmt":"2021-06-22T20:19:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/"},"modified":"2021-06-22T16:19:30","modified_gmt":"2021-06-22T20:19:30","slug":"regeneron-to-participate-in-guggenheim-biopharma-strategy-series","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/","title":{"rendered":"Regeneron to Participate in Guggenheim Biopharma Strategy Series"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n TARRYTOWN, N.Y.<\/span>, June 22, 2021<\/span> \/PRNewswire\/ — Regeneron Pharmaceuticals, Inc. (NASDAQ:\u00a0<\/b>REGN)\u00a0is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series \u2013 Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation \u2013 at 10:00 a.m. ET on Tuesday<\/span>, June 29, 2021.\u00a0 \u00a0<\/p>\n

A live audio webcast will be available on the ‘Investors and Media’ page of Regeneron’s website at http:\/\/investor.regeneron.com\/events-and-presentations<\/a>.\u00a0 A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.\u00a0 <\/p>\n

\n About<\/b>\u00a0Regeneron
<\/b>Regeneron\u00a0(NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.<\/p>\n

Regeneron is accelerating and improving the traditional drug development process through our proprietary\u00a0VelociSuite\u00ae<\/sup><\/i>\u00a0technologies, such as\u00a0VelocImmune\u00ae<\/sup><\/i>, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.<\/p>\n

For additional information about the company, please visit\u00a0www.regeneron.com<\/a>\u00a0or follow @Regeneron on Twitter.<\/p>\n

\n Contact Information:
<\/b>Investor Relations
Justin Holko<\/span>
914.847.7786
justin.holko@regeneron.com<\/a><\/p>\n

\u00a0<\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series-301317654.html<\/a><\/p>\n

SOURCE Regeneron Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire TARRYTOWN, N.Y., June 22, 2021 \/PRNewswire\/ — Regeneron Pharmaceuticals, Inc. (NASDAQ:\u00a0REGN)\u00a0is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series \u2013 Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation \u2013 at 10:00 a.m. ET on Tuesday, June 29, 2021.\u00a0 \u00a0 A live audio webcast will be available on the ‘Investors and Media’ page of Regeneron’s website at http:\/\/investor.regeneron.com\/events-and-presentations.\u00a0 A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.\u00a0 About\u00a0RegeneronRegeneron\u00a0(NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and … <\/p>\n

Continue reading “Regeneron to Participate in Guggenheim Biopharma Strategy Series”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-505659","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRegeneron to Participate in Guggenheim Biopharma Strategy Series - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron to Participate in Guggenheim Biopharma Strategy Series - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TARRYTOWN, N.Y., June 22, 2021 \/PRNewswire\/ — Regeneron Pharmaceuticals, Inc. (NASDAQ:\u00a0REGN)\u00a0is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series \u2013 Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation \u2013 at 10:00 a.m. ET on Tuesday, June 29, 2021.\u00a0 \u00a0 A live audio webcast will be available on the ‘Investors and Media’ page of Regeneron’s website at http:\/\/investor.regeneron.com\/events-and-presentations.\u00a0 A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.\u00a0 About\u00a0RegeneronRegeneron\u00a0(NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and … Continue reading "Regeneron to Participate in Guggenheim Biopharma Strategy Series"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-22T20:19:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY19231&sd=2021-06-22\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Regeneron to Participate in Guggenheim Biopharma Strategy Series\",\"datePublished\":\"2021-06-22T20:19:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY19231&sd=2021-06-22\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/\",\"name\":\"Regeneron to Participate in Guggenheim Biopharma Strategy Series - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY19231&sd=2021-06-22\",\"datePublished\":\"2021-06-22T20:19:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY19231&sd=2021-06-22\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=NY19231&sd=2021-06-22\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron to Participate in Guggenheim Biopharma Strategy Series\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron to Participate in Guggenheim Biopharma Strategy Series - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/","og_locale":"en_US","og_type":"article","og_title":"Regeneron to Participate in Guggenheim Biopharma Strategy Series - Market Newsdesk","og_description":"PR Newswire TARRYTOWN, N.Y., June 22, 2021 \/PRNewswire\/ — Regeneron Pharmaceuticals, Inc. (NASDAQ:\u00a0REGN)\u00a0is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series \u2013 Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation \u2013 at 10:00 a.m. ET on Tuesday, June 29, 2021.\u00a0 \u00a0 A live audio webcast will be available on the ‘Investors and Media’ page of Regeneron’s website at http:\/\/investor.regeneron.com\/events-and-presentations.\u00a0 A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.\u00a0 About\u00a0RegeneronRegeneron\u00a0(NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and … Continue reading \"Regeneron to Participate in Guggenheim Biopharma Strategy Series\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-22T20:19:30+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY19231&sd=2021-06-22","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Regeneron to Participate in Guggenheim Biopharma Strategy Series","datePublished":"2021-06-22T20:19:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY19231&sd=2021-06-22","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/","name":"Regeneron to Participate in Guggenheim Biopharma Strategy Series - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY19231&sd=2021-06-22","datePublished":"2021-06-22T20:19:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY19231&sd=2021-06-22","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY19231&sd=2021-06-22"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-to-participate-in-guggenheim-biopharma-strategy-series\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron to Participate in Guggenheim Biopharma Strategy Series"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/505659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=505659"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/505659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=505659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=505659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=505659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}